Sten Wingren

2.7k total citations
63 papers, 2.1k citations indexed

About

Sten Wingren is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Sten Wingren has authored 63 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 22 papers in Cancer Research and 21 papers in Molecular Biology. Recurrent topics in Sten Wingren's work include Estrogen and related hormone effects (13 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer-related Molecular Pathways (11 papers). Sten Wingren is often cited by papers focused on Estrogen and related hormone effects (13 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer-related Molecular Pathways (11 papers). Sten Wingren collaborates with scholars based in Sweden, Ireland and Norway. Sten Wingren's co-authors include Bo Nordenskjöld, Olle Stål, John Carstensen, Pia Wegman, Lambert Skoog, Thomas Hatschek, Lars Erik Rutqvist, Elingarami Sauli, Xiao‐Feng Sun and Peter Söderkvist and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Sten Wingren

62 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sten Wingren Sweden 24 1.0k 701 625 581 443 63 2.1k
E. Berns Netherlands 23 921 0.9× 1.0k 1.5× 763 1.2× 488 0.8× 232 0.5× 42 2.0k
Rosemary L. Balleine Australia 23 791 0.8× 649 0.9× 481 0.8× 680 1.2× 186 0.4× 58 2.0k
Carol L. Rosenberg United States 26 1.1k 1.0× 944 1.3× 750 1.2× 552 1.0× 565 1.3× 39 2.3k
Ye Xu China 23 568 0.6× 954 1.4× 666 1.1× 379 0.7× 161 0.4× 90 1.7k
M. E. Lippman United States 24 998 1.0× 919 1.3× 599 1.0× 563 1.0× 240 0.5× 57 2.1k
Björn Erikstein Norway 24 1.3k 1.3× 859 1.2× 702 1.1× 968 1.7× 176 0.4× 47 2.7k
Hiroshi Sonoo Japan 26 1.3k 1.3× 820 1.2× 645 1.0× 476 0.8× 277 0.6× 123 2.3k
Iñigo Landa United States 24 983 1.0× 1.0k 1.5× 406 0.6× 602 1.0× 363 0.8× 46 3.0k
Maria Luisa Veronese United States 18 678 0.7× 969 1.4× 190 0.3× 351 0.6× 262 0.6× 35 1.8k
Shunzo Kobayashi Japan 28 1.2k 1.1× 1.1k 1.6× 786 1.3× 716 1.2× 237 0.5× 74 2.3k

Countries citing papers authored by Sten Wingren

Since Specialization
Citations

This map shows the geographic impact of Sten Wingren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sten Wingren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sten Wingren more than expected).

Fields of papers citing papers by Sten Wingren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sten Wingren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sten Wingren. The network helps show where Sten Wingren may publish in the future.

Co-authorship network of co-authors of Sten Wingren

This figure shows the co-authorship network connecting the top 25 collaborators of Sten Wingren. A scholar is included among the top collaborators of Sten Wingren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sten Wingren. Sten Wingren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wingren, Sten, et al.. (2014). Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics. 9(8). 1149–1162. 50 indexed citations
2.
3.
Wingren, Sten, et al.. (2012). DNA methylation pattern of theSLC25A43gene in breast cancer. Epigenetics. 7(3). 300–306. 15 indexed citations
4.
Wegman, Pia, et al.. (2007). In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients. Breast Cancer Research and Treatment. 112(1). 15–23. 9 indexed citations
5.
Wegman, Pia, et al.. (2005). Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women. Journal of Cancer Research and Clinical Oncology. 131(7). 439–444. 41 indexed citations
6.
Sundquist, M., Sten Thorstenson, Lars Brudin, Sten Wingren, & Bo Nordenskjöld. (2001). Incidence and prognosis in early-onset breast cancer. European Journal of Cancer. 37. 41–42. 1 indexed citations
7.
Gentile, Marco, Karen Ege Olsen, Monika Dufmats, & Sten Wingren. (1999). Frequent allelic losses at 11q24.1–q25 in young women with breast cancer: association with poor survival. British Journal of Cancer. 80(5-6). 843–849. 27 indexed citations
8.
Wingren, Sten, et al.. (1997). Frequent allelic losses on chromosome 13q in human male breast carcinomas. European Journal of Cancer. 33(14). 2393–2396. 8 indexed citations
9.
Karlsson, Margareta, Ulf Jungnelius, Steinar Aamdal, et al.. (1996). Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma. International Journal of Cancer. 65(1). 1–5. 32 indexed citations
10.
Stål, Olle, Marie Stenmark Askmalm, Sten Wingren, et al.. (1995). P53 Expression and the Result of Adjuvant Therapy of Breast Cancer. Acta Oncologica. 34(6). 767–770. 32 indexed citations
11.
Stål, Olle, Sten Wingren, Lambert Skoog, et al.. (1995). c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. European Journal of Cancer. 31(13-14). 2185–2190. 111 indexed citations
12.
Stål, Olle, Lambert Skoog, Lars Erik Rutqvist, et al.. (1994). S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. British Journal of Cancer. 70(6). 1258–1262. 49 indexed citations
13.
Stål, Olle, et al.. (1994). Simultaneous analysis of c‐erbB‐2 expression and DNA content in breast cancer using flow cytometry. Cytometry. 16(2). 160–168. 28 indexed citations
14.
Wingren, Sten, et al.. (1994). S‐phase fraction after gating on epithelial cells predicts recurrence in node‐negative breast cancer. International Journal of Cancer. 59(1). 7–10. 17 indexed citations
15.
Wingren, Sten, et al.. (1994). Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. British Journal of Cancer. 69(3). 546–549. 21 indexed citations
16.
Wingren, Sten, et al.. (1994). S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence. Breast Cancer Research and Treatment. 29(2). 179–187. 12 indexed citations
17.
Karlsson, Margareta, et al.. (1993). DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. British Journal of Cancer. 67(1). 134–138. 11 indexed citations
18.
Walz, Thomas, Avni Abdiu, Sten Wingren, et al.. (1991). Suramin inhibits growth of human osteosarcoma xenografts in nude mice.. PubMed. 51(13). 3585–9. 29 indexed citations
19.
Xiao, Sun, Sten Wingren, John Carstensen, et al.. (1991). ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma. European Journal of Cancer and Clinical Oncology. 27(12). 1646–1649. 15 indexed citations
20.
Stål, Olle, Sten Wingren, John Carstensen, et al.. (1989). Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. European Journal of Cancer and Clinical Oncology. 25(2). 301–309. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Berns Breakdown of academic impact, for papers by Rosemary L. Balleine Breakdown of academic impact, for papers by Carol L. Rosenberg Breakdown of academic impact, for papers by Ye Xu Breakdown of academic impact, for papers by M. E. Lippman Breakdown of academic impact, for papers by Björn Erikstein Breakdown of academic impact, for papers by Hiroshi Sonoo Breakdown of academic impact, for papers by Iñigo Landa Breakdown of academic impact, for papers by Maria Luisa Veronese Breakdown of academic impact, for papers by Shunzo Kobayashi
Rankless by CCL
2026